Search clinical trials for: erlotinib HCl

Total 4141 results

European Organisation for Research and Treatment...

Completed

Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

France, Spain, Netherlands, Australia, United Kingdom, Italy, Portugal, Austria
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma

Stage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage I Colon Cancer | Stage... and other conditions

United States
H. Lee Moffitt Cancer Center and Research Institute

Terminated

Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas

Glioma | Astrocytoma | Oligodendroglioma

United States
First People's Hospital of Hangzhou
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of Anlotinib in the Treatment of Recurrent High-grade Glioma

Recurrent High-grade Glioma

China
Peng Yuan

Completed

Anlotinib in Metastatic HER2 Negative Breast Cancer

Breast Neoplasm | Antineoplastic Agents | Anlotinib

China
Hunan Cancer Hospital
Henan Cancer Hospital; Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors

Non Small Cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)

Medullary Thyroid Carcinoma

China
Centre Hospitalier Sud Francilien

Completed

Real-world Use of Hybrid Closed Loop in Adolescents and Young Adults 15-25 Years of Age With Type 1 Diabetes (BFHado)

Type1 Diabetes | Adolescents | Young Adults

France
Cortexyme Inc.

Completed

A Multiple Ascending Dose Study of COR388

Alzheimer Disease

United States
Dendreon

Completed

Dose Escalation Study of EC D-3263 HCl in Advanced Solid Tumors

Solid Tumors

United States
Indiana University
OSI Pharmaceuticals

Completed

Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia

Leukemia, Myelomonocytic, Acute

United States
Weill Medical College of Cornell University
OSI Pharmaceuticals

Completed

Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer

Carcinoma, Non-small Cell Lung

United States
Hoffmann-La Roche

Completed

A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations

Non-Squamous Non-Small Cell Lung Cancer

Hong Kong, Korea, Republic of, Taiwan, Thailand
Baohui Han

Completed

Erlotinib as Neoadjuvant Treatment in Patients With Stage ⅢA N2 NSCLC With Activating EGFR Mutation. (ML25444)

Non Small Cell Lung Cancer

China
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Metastatic and/or Recurrent Head and Neck Cancer

Head and Neck Cancer

Spain, United States
Hoffmann-La Roche

Completed

A Non-interventional Trial of Erlotinib (Tarceva) Metastatic Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer

Austria
Hoffmann-La Roche

Completed

An Observational Study of Erlotinib (Tarceva) as Second-line Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Pemetrexed in First-line Therapy (TIME)

Non-Squamous Non-Small Cell Lung Cancer

Belgium
Memorial Sloan Kettering Cancer Center

Terminated

Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib

Lung Cancer

United States
Li Zhang

Unknown

Evaluate Erlotinib Efficacy and Safety as the 2nd/3rd Treatment in NSCLC With EGFR M(-) and C-met(-)

Non-small Cell Lung Cancer

China
Rigshospitalet, Denmark
Hoffmann-La Roche

Terminated

Erlotinib as First-line Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) for Patients Unfit for Chemotherapy

Non Small Cell Lung Cancer

Denmark
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; Second Affiliated Hospital...

Unknown

Intermittent and Maintenance of Erlotinib in Combination With Pemetrexed/Carboplatin in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

Lung, Carcinoma
National Cancer Institute (NCI)
NCIC Clinical Trials Group

Completed

Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer

Endometrial Cancer

Canada
Mayo Clinic
Genentech, Inc.

Completed

Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC)

Cholangiocarcinoma | Primary Sclerosing Cholangitis | Chemoprevention | Trisomy 7

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer

Gastric Cancer | Esophageal Cancer

United States, Canada
Grupo Gallego de Investigaciones Oncologicas

Completed

Trial to Evaluate the Efficacy and Safety of Tarceva and Capecitabine in Advanced Pancreatic Cancer Patients (XELTA)

Metastatic Adenocarcinoma of the Pancreas

Spain
Ohio State University Comprehensive Cancer Center
Genentech, Inc.; National Comprehensive Cancer Network

Completed

Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

Breast Cancer

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients

Advanced Solid Tumors

China
Eli Lilly and Company

Completed

A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer

Non-Small Cell Lung Cancer | Malignant Solid Tumor

United States
Sun Yat-sen University

Terminated

IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain Metastases

Non-Small Cell Lung Carcinoma

China
University Health Network, Toronto
National Cancer Institute (NCI)

Completed

Erlotinib and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Head and Neck Cancer

Canada
Memorial Sloan Kettering Cancer Center

Completed

Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations

Oligometastatic Lung Adenocarcinoma

United States
Hoffmann-La Roche

Completed

An Observational Study of Tarceva (Erlotinib) in Participants With Locally Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer (ELEMENT) (ELEMENT)

Non-Squamous Non-Small Cell Lung Cancer

Serbia
Hoffmann-La Roche

Completed

A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC) (MERIT)

Non-Squamous Non-Small Cell Lung Cancer

Hong Kong, Spain, Russian Federation, France, Bulgaria, Germany, Estonia, Italy, Poland, Taiwan, United Kingdom, Singapore, Ireland, Belgium
Hoffmann-La Roche

Completed

A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

Australia, China, Korea, Republic of, Denmark, Germany, Greece, Russian Federation, Hungary, France, Netherlands, New Zealand, Spain, Austria, Slovakia, United Kingdom, Malaysia, Belgium, Lithuania, South Africa, Slovenia, Italy, ... and more
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Breast Cancer

United States
Atacama Therapeutics

Completed

Exploratory Study to Assess the Efficacy and Safety of TC-5214 in the Treatment of Subjects With Palmar Hyperhidrosis

Palmar Hyperhidrosis

United States
Stealth BioTherapeutics Inc.

Recruiting

ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD) (ReNEW)

Age-Related Macular Degeneration

United States
Amicus Therapeutics

Approved for marketing

Physician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry Disease

Fabry Disease

United States, Australia
Artax Biopharma Inc
Simbec Research; ORION Clinical Services; Packaging Coordinators Inc; Centro de...

Completed

Safety Study of Immune System Modulator for Autoimmune Diseases

Healthy Volunteers

United Kingdom
Helsinn Therapeutics (U.S.), Inc

Completed

Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia.

Cancer Cachexia

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States
First Hospital of Shijiazhuang City

Unknown

Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative

Carcinoma | Non-small Cell Lung Cancer | Lung Neoplasm

China
National Guard Health Affairs

Suspended

Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer (REALME)

Non-small Cell Lung Cancer Metastatic

Saudi Arabia
University of Virginia
Juvenile Diabetes Research Foundation

Completed

Hybrid Closed-Loop Control With Smart Prandial Insulin Dosing in Type 1 Diabetes

Type 1 Diabetes

United States
Eisai Inc.

Completed

Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States, Hong Kong, Taiwan, Korea, Republic of, Singapore, Thailand, Malaysia
National Cancer Center, Korea
Hoffmann-La Roche

Active, not recruiting

Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations

NSCLC Stage II | NSCLC, Stage IIIA

Korea, Republic of
David M. Jackman, MD
Beth Israel Deaconess Medical Center; Genentech, Inc.; Brigham and Women's Hospital

Completed

Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC

Non-small Cell Lung Cancer

United States
Pfizer

Completed

A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen

Non-small Cell Lung Cancer

United States, Taiwan, Korea, Republic of, Australia, Brazil, Spain, United Kingdom, Singapore, Canada, Hong Kong, Poland, Puerto Rico
Hoffmann-La Roche

Completed

A Study of Tarceva (Erlotinib) to Compare Two Different Doses in in Currently Smoking Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (CURRENTS)

Non-Small Cell Lung Cancer

Spain, France, Germany, Switzerland, China, Turkey, Denmark, Egypt, Netherlands

Search clinical trials for: erlotinib HCl

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Equatorial Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations